Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
848259-27-8
|
| gptkbp:developedBy |
gptkb:Achillion_Pharmaceuticals
treatment of hepatitis C |
| gptkbp:hasMolecularFormula |
C27H24ClN5O3S
|
| gptkbp:hasSMILES |
COc1ccc2c(c1)nc(n2C)C(=O)C(NC(=O)C3CC3)C(Cc4ccccc4)NC(=O)c5csc(NC6=CC=C(Cl)C=C6)n5
|
| gptkbp:hasUNII |
6Q1K1Q1K0E
|
| https://www.w3.org/2000/01/rdf-schema#label |
ACH-1625
|
| gptkbp:IUPACName |
(2R)-2-[(1R)-1-({(1S)-1-[(cyclopropylcarbonyl)amino]-2-phenylethyl}amino)-2-(6-methoxy-2-methyl-1H-benzimidazol-1-yl)-2-oxoethyl]-N-(4-chlorophenyl)thiazole-4-carboxamide
|
| gptkbp:mechanismOfAction |
NS3 protease inhibitor
|
| gptkbp:molecularWeight |
533.03 g/mol
|
| gptkbp:PubChem_CID |
25154816
25000000 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational drug
|
| gptkbp:synonym |
gptkb:Sovaprevir
|
| gptkbp:bfsParent |
gptkb:NS3/4A_serine_protease
gptkb:Achillion_Pharmaceuticals |
| gptkbp:bfsLayer |
7
|